search
Back to results

sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

Primary Purpose

Wilsons Disease

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Fibroscan
Ultrasound
Galactose
Liver biopsy
Functional hepatic nitrogen clearance
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Wilsons Disease focused on measuring sCD163, liver cirrhosis, disease severity

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • diagnosed with Wilsons disease

Exclusion Criteria:

-

Sites / Locations

  • Department of Hepatology and Gastroenterology, Aarhus University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Wilsons disease

Arm Description

All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.

Outcomes

Primary Outcome Measures

Measurement of the macrophage activation markers sCD163
For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.
Measurement of soluble mannose receptor (sMR)
For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.

Secondary Outcome Measures

Urinary copper excretion in 24 hour urine collection
The patient collects urine for 24 hours at home in a designated container, which is handed out at the department. The container is kept refrigerated and is brought to the control
Ultrasound is performed for signs of liver cirrhosis.
Ultrasound is a non-invasive procedure. Signs og liver cirrhosis by ultrasound are surface modularity, a smaller liver, heterogeneous echo texture and signs of portal hypertension.
Fibroscan is performed to evaluate liver stiffness (fibrosis)
Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure.
Continous Reaction Time to evaluate brain dysfunction
Continous Reaction Time is a computerized 10 minutes test that measures and combines motor reaction speed and sustained attention.
Galactose elimination capacity is performed to evaluate metabolic liver function
The metabolic liver function test Galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Histological disease activity at time of diagnosis and liver biopsy, evaluating if any liver fibrosis
Liver fibrosis will be also be determined on liver biopsies.
Functional hepatic nitrogen clearance to evaluate metabolic liver function
Functional hepatic nitrogen clearancerequires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours. It evaluates the metabolic liver function by measuring the clearance of alanine from blod by analyzing the amount og urea in the urine collected 4 hours after the start og the alanine infusion.
The Portosystemic Encephalopathy to evaluate brain dysfunction
The Portosystemic Encephalopathy test is a 15-minute paper-pencil test battery comprised of 5 sub-tests: Digit Symbol test (DST), Number Connection Test A (NCT-A), Number Connection Test B (NCT-B), Serial Dotting Test (SDOT), and Line Tracing Test (LTT, time and errors).

Full Information

First Posted
February 26, 2016
Last Updated
November 1, 2022
Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02702765
Brief Title
sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis
Official Title
Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
February 2016 (Actual)
Primary Completion Date
February 2020 (Actual)
Study Completion Date
February 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim is to investigate macrophage activation markers and correlations to liver fibrosis in patients with Wilsons Disease. Researchers wish to investigate associations to neurologic and metabolic liver function. Researchers will assess this by comparing blood samples with fibrosis and liver function analyses. This study provides new insight into macrophages and their involvement in Wilsons Disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wilsons Disease
Keywords
sCD163, liver cirrhosis, disease severity

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
33 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Wilsons disease
Arm Type
Experimental
Arm Description
All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
Intervention Type
Procedure
Intervention Name(s)
Fibroscan
Intervention Description
Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
Intervention Type
Procedure
Intervention Name(s)
Ultrasound
Intervention Description
Ultrasound is a non-invasive procedure
Intervention Type
Drug
Intervention Name(s)
Galactose
Other Intervention Name(s)
Galactose elimination capacity
Intervention Description
Galactose elimination capacity is performed to evaluate metabolic liver function. The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Intervention Type
Procedure
Intervention Name(s)
Liver biopsy
Intervention Description
Histological disease activity at time of diagnosis evaluating if any liver fibrosis
Intervention Type
Procedure
Intervention Name(s)
Functional hepatic nitrogen clearance
Intervention Description
Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
Primary Outcome Measure Information:
Title
Measurement of the macrophage activation markers sCD163
Description
For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
Measurement of soluble mannose receptor (sMR)
Description
For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.
Time Frame
Baseline, 1 year, 2 year, 3 year
Secondary Outcome Measure Information:
Title
Urinary copper excretion in 24 hour urine collection
Description
The patient collects urine for 24 hours at home in a designated container, which is handed out at the department. The container is kept refrigerated and is brought to the control
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
Ultrasound is performed for signs of liver cirrhosis.
Description
Ultrasound is a non-invasive procedure. Signs og liver cirrhosis by ultrasound are surface modularity, a smaller liver, heterogeneous echo texture and signs of portal hypertension.
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
Fibroscan is performed to evaluate liver stiffness (fibrosis)
Description
Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure.
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
Continous Reaction Time to evaluate brain dysfunction
Description
Continous Reaction Time is a computerized 10 minutes test that measures and combines motor reaction speed and sustained attention.
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
Galactose elimination capacity is performed to evaluate metabolic liver function
Description
The metabolic liver function test Galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
Histological disease activity at time of diagnosis and liver biopsy, evaluating if any liver fibrosis
Description
Liver fibrosis will be also be determined on liver biopsies.
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
Functional hepatic nitrogen clearance to evaluate metabolic liver function
Description
Functional hepatic nitrogen clearancerequires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours. It evaluates the metabolic liver function by measuring the clearance of alanine from blod by analyzing the amount og urea in the urine collected 4 hours after the start og the alanine infusion.
Time Frame
Baseline, 1 year, 2 year, 3 year
Title
The Portosystemic Encephalopathy to evaluate brain dysfunction
Description
The Portosystemic Encephalopathy test is a 15-minute paper-pencil test battery comprised of 5 sub-tests: Digit Symbol test (DST), Number Connection Test A (NCT-A), Number Connection Test B (NCT-B), Serial Dotting Test (SDOT), and Line Tracing Test (LTT, time and errors).
Time Frame
Baseline, 1 year, 2 year, 3 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosed with Wilsons disease Exclusion Criteria: -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Henning Grønbæk, Professor
Organizational Affiliation
Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark, 8000
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Hepatology and Gastroenterology, Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8000
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
30241550
Citation
Bjorklund J, Laursen TL, Sandahl TD, Moller HJ, Vilstrup H, Ott P, Gronbaek H. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study. Orphanet J Rare Dis. 2018 Sep 21;13(1):169. doi: 10.1186/s13023-018-0910-7.
Results Reference
derived

Learn more about this trial

sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

We'll reach out to this number within 24 hrs